Resource Center

Ten Most Common Reasons for FDA 483 Inspectional Observations in Pharmaceutical Environments

Ten Most Common Reasons for FDA 483 Inspectional Observations in Pharmaceutical Environments

Cover Image of Ten Most Common Reasons for FDA 483 Inspectional Observations in Pharmaceutical Environments Document
About This Document

The U.S. Food and Drug Administration (FDA) has released data on the most common observations it makes during inspections of pharmaceutical facilities. The top ten deficiencies are explored in this insightful white paper.